Results 181 to 190 of about 26,259 (260)

First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract First‐line (1L) bendamustine plus rituximab (BR) leads to high response rates in follicular lymphoma (FL), but maintaining durable remissions remains challenging. We report the 3‐year follow‐up from arm 3 of the phase 1b/2 EPCORE NHL‐2 trial (NCT04663347) of epcoritamab, a subcutaneously administered CD3×CD20 bispecific antibody, combined with
Umberto Vitolo, Lorenzo Falchi, Per‐Ola Andersson, Marcel Nijland, Fritz Offner, Sylvia Snauwaert, Jacob H. Christensen, Michael R. Clausen, Alexander Fosså, Pilar G. Prieto, Eliza A. Hawkes, Judit M. Jørgensen, Yasmin H. Karimi, Catharina Lewerin, Joost S. P. Vermaat, Björn E. Wahlin, Poliana Patah, Christopher Morehouse, Malene Risum, Zhu Li, Jennifer Marek, Joshua D. Brody   +21 more
wiley   +1 more source

Outpatient step-up dosing of bispecific antibodies in relapsed or refractory multiple myeloma: an oncology nursing framework for monitoring and supportive care. [PDF]

Front Oncol
Song Y, Zhou X, Wang L.
europepmc   +1 more source

Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline. [PDF]

BioDrugs
Shastri T, Trabolsi A, Arumov A, Schatz JH.   +3 more
europepmc   +1 more source

Real-world resource utilization, toxicity management, and efficacy outcomes of CD20 × CD3 bispecific antibodies in B-cell lymphoma: A study from the GELTAMO network. [PDF]

Hemasphere
Bastos-Oreiro M, Iacoboni G, Navarro V, Martínez C, Manresa P, Magnano L, Jiménez-Ubieto A, Vázquez S, Rodriguez MJ, Busnego MT, Del Campo R, Paúl PJ, Murillo I, Donato EM, Serna A, Luzardo H, Gómez P, Pérez E, Mendibil B, Ramos S, García-Noblejas A, Gonzalez de Villambrosia S, Díaz FJ, López J, Martín-Moro F, Fernandez-Caldas P, Fernandez R, Gutierrez A, Sánchez B, Domínguez N, Civeira M, Villafuerte P, Olazabal I, Zeberio I, Barrenetxea C, Gutierrez N, Romero S, Martín-Consuegra S, Huerga S, Golbano N, Riaza R, Hueso JA, Martinez-Barranco P, Navarro B, Villalón L, Ortega P, Torres A, Ormenazabal I, Sanchez Anton MP, Goñi MA, Abrisqueta P, Martín García-Sancho A.   +51 more
europepmc   +1 more source

Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirements. [PDF]

J Clin Invest
DiNapoli SR, Wright KM, Mog BJ, Pearlman AH, Nichakawade TD, Marcou N, Hsiue EH, Hwang MS, Douglass J, Liu Q, Watson E, Dal Molin M, Cohen JD, Popoli M, Paul S, Konig MF, Wyhs N, Azurmendi PA, Glavaris S, Ge J, Awosika TO, Liu J, Gabrielson KL, Gabelli SB, Pardoll DM, Bettegowda C, Papadopoulos N, Kinzler KW, Zhou S, Vogelstein B.   +29 more
europepmc   +1 more source

The Role of Precision Medicine in Neuroblastoma: Targeted Therapies and Personalized Approaches—A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Neuroblastoma is the most common extracranial solid tumor and contributes the most to pediatric oncology deaths worldwide. Its clinical manifestations are heterogeneous, including relapses, and the prognosis remains poor, especially for high‐risk patients.
Mosammat Jannatul Mawa, Mohammad Shahangir Biswas, Maksudul Haque, Munna Kumar Podder   +3 more
wiley   +1 more source

Toxicities associated with lymphoma-targeting bispecific antibodies-a review. [PDF]

Front Med (Lausanne)
Doig C, Yannakou CK.
europepmc   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

The Landscape of Bispecific Antibodies in Solid Tumor Oncology: Trends, Challenges, and Opportunities. [PDF]

Cancer Med
ElBeblawy R, Jani C, Pérez-Granado J, Gramling M, Desai A.   +4 more
europepmc   +1 more source

Mitigating Teclistamab Toxicity: Prophylactic Tocilizumab and Timing of Immunoglobulin Replacement Therapy in a Nationwide Cohort

American Journal of Hematology, Volume 101, Issue 8, Page 2081-2085, August 2026.
Astrid Hundebøll Torpe, Jonathan Thorsen, Gustav Mathiasen, Katrine Fladeland Iversen, Sarah Farmer, Thomas Lund, Charlotte Toftmann Hansen, Lene Kongsgaard Nielsen, Nicolai Grønne Dahlager Jørgensen, Maja Ølholm Vase, Elena Manuela Teodorescu, Morten Salomo, Christina Wennerström, Tobias S. Slørdahl, Agoston Gyula Szabo   +14 more
wiley   +1 more source